Dimerix enters agreement for new trial of DMX-200 in diabetic kidney disease


Dimerix (ASX:DXB) has entered into an agreement with The Australian Centre for Accelerating Diabetes Innovations (ACADI) to progress its DMX-200 into a new clinical trial in patients with diabetic kidney disease.

The company said this new trial will provide another potential market opportunity for Dimerix in addition to its other Phase 3 trials currently underway.

ACADI was established in January 2022 through $10 million in funding from the federal government's Medical Research Future Fund. It has also received $13.3 million in cash and in-kind contributions from 70 partners across the country.

The centre aims to accelerate innovations to improve the lives of people with or at risk of diabetic kidney disease. It is led by Associate Professor Elif Ekinci from the University of Melbourne, an investigator on the Dimerix DMX-200 Phase 2 study completed in 2020.

Dimerix said the clinical trial protocol is currently being finalised and is expected to be a 12-24 months study of proteinuria and eGFR (kidney function) in patients with diabetic kidney disease. The study plans to recruit across Australia and is expected to commence in the fourth quarter of 2022.

"The results of our Phase 2 study in diabetic kidney disease were reported in the 2021 financial year, with 30% of all participants falling below the threshold for diabetic kidney disease diagnosis by the end of the study - a fantastic outcome for those patients. It also appeared that protein levels in the urine appeared to be continuing to trend downwards at the end of both DMX-200 treatment periods, which indicated that a longer study treatment duration was warranted," said Dimerix CEO and managing director Dr Nina Webster.